0
Your cart

Your cart is empty

Books > Law > Laws of other jurisdictions & general law > Social law

Buy Now

Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law (Hardcover, 1st ed. 2021) Loot Price: R3,871
Discovery Miles 38 710
Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law (Hardcover, 1st ed. 2021): Daria Kim

Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law (Hardcover, 1st ed. 2021)

Daria Kim

Series: Munich Studies on Innovation and Competition, 16

 (sign in to rate)
Loot Price R3,871 Discovery Miles 38 710 | Repayment Terms: R363 pm x 12*

Bookmark and Share

Expected to ship within 12 - 17 working days

This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised.

General

Imprint: Springer Nature Switzerland AG
Country of origin: Switzerland
Series: Munich Studies on Innovation and Competition, 16
Release date: October 2021
First published: 2021
Authors: Daria Kim
Dimensions: 235 x 155mm (L x W)
Format: Hardcover
Pages: 300
Edition: 1st ed. 2021
ISBN-13: 978-3-03-086777-5
Categories: Books > Law > International law > General
Books > Law > Laws of other jurisdictions & general law > Social law > General
Books > Medicine > General issues > Medical equipment & techniques > Medical research
LSN: 3-03-086777-3
Barcode: 9783030867775

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners